Podoplanin is a useful marker for identifying mesothelioma in malignant effusions
dc.contributor.author | Hanna, Atef N. | en_US |
dc.contributor.author | Pang, Yijun | en_US |
dc.contributor.author | Bedrossian, Carlos W. M. | en_US |
dc.contributor.author | Dejmek, Annika | en_US |
dc.contributor.author | Michael, Claire W. | en_US |
dc.date.accessioned | 2010-04-14T20:04:45Z | |
dc.date.available | 2011-03-01T16:26:47Z | en_US |
dc.date.issued | 2010-04 | en_US |
dc.identifier.citation | Hanna, Atef; Pang, Yijun; Bedrossian, Carlos W. M.; Dejmek, Annika; Michael, Claire W. (2010). "Podoplanin is a useful marker for identifying mesothelioma in malignant effusions." Diagnostic Cytopathology 38(4): 264-269. <http://hdl.handle.net/2027.42/69197> | en_US |
dc.identifier.issn | 8755-1039 | en_US |
dc.identifier.issn | 1097-0339 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/69197 | |
dc.description.abstract | The diagnosis of malignant mesothelioma in serosal effusions continues to be a major challenge because some of its cytomorphological features closely resemble adenocarcinomas. Immunohistochemistry is a valuable tool in the differentiation of epithelioid mesothelioma from metastatic adenocarcinomas. However, no single antibody has demonstrated absolute sensitivity or specificity. In this study, we evaluated the value of immunostaining pattern for podoplanin to differentiate mesothelioma from adenocarcinomas of various origins. Cell blocks from previously collected paraffin-embedded cell blocks of 86 effusions (18 mesothelioma, 35 reactive mesothelium, 9 breast adenocarcinoma, 14 ovarian adenocarcinoma, and 10 lung adenocarcinoma) were retrieved from the file of the Department of Pathology at University of Michigan and Lund University in Sweden and were used for the study. Slides prepared from the cell blocks were stained for podoplanin. The percentage of immunostained cells was recorded as follows: 1+ (5–25%), 2+ (26–50%), and 3+ (>50%). A stain result involving <5% of cells was considered negative. The intensity of positive results was evaluated as strong, moderate, or weak. Podoplanin is expressed in 94% of malignant mesothelioma cases (17/18), 97% (30/31) of cases of reactive mesothelial, 0% of lung adenocarcinoma cases (0/9), 0% of breast adenocarcinoma (0/9), and 7% of ovarian adenocarcinoma (1/14). All positive cases of malignant mesothelioma and reactive mesothelium showed strong membranous reactivity to podoplanin. The one positive case of ovarian adenocarcinoma showed a weak membranous podoplanin immunostaining. On the basis of our results and published data, we believe that membranous podoplanin immunoreactivity, in conjunction with calretinin, would be more specific than CK5/6 and WT-1 in differentiating epithelioid malignant mesothelioma from adenocarcinoma of the lung, breast, and ovary. Diagn. Cytopathol. 2010. © 2010 Wiley-Liss, Inc. | en_US |
dc.format.extent | 275880 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Podoplanin is a useful marker for identifying mesothelioma in malignant effusions | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pathology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pathology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Pathology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Pathology, University of Michigan, Ann Arbor, Michigan ; Professor Director, Cytopathology 1500 East Medical Center Drive, Room 2G332 UH, Box 0054, Ann Arbor, MI 48109-0054 | en_US |
dc.contributor.affiliationother | Rush Presbyterian Hospital, Chicago, Illinois | en_US |
dc.contributor.affiliationother | Department of Laboratory Medicine, Division of Pathology, Malmo University Hospital, Lund University, Sweden | en_US |
dc.identifier.pmid | 20146302 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/69197/1/21340_ftp.pdf | |
dc.identifier.doi | 10.1002/dc.21340 | en_US |
dc.identifier.source | Diagnostic Cytopathology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.